Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.

摘要: This paper presents a summary of the evidence review group report into clinical effectiveness and cost-effectiveness rituximab for treatment relapsed or refractory stage III IV follicular non-Hodgkin's lymphoma (NHL), in accordance with licensed indication, based upon submission from Roche Products Ltd to National Institute Health Clinical Excellence (NICE) as part single technology appraisal (STA) process. The submitted included two randomised controlled trials [European Organisation Research Treatment Cancer (EORTC) German Low Grade Lymphoma Study Group - Fludarabine, Cyclophosphamide Mitoxantrone (GLSG-FCM)] comparing effects chemotherapy without induction remission at first second relapse benefits maintenance therapy versus NHS's current practice observation (FL) patients. Both showed that patients FL addition increased overall response rates. Furthermore, median length when compared only. Safety data while majority reported some adverse events, number withdrawing EORTC trial was low, rates not being GLSG-FCM trial. most commonly events were blood/bone marrow toxicity, skin rashes allergies. ERG reran manufacturer's economic model after altering several assumptions parameter values order recalculate cost-utility ratios, quality-adjusted life-years (QALYs) estimates benefits. manufacturer cost-effective against applied thresholds, an incremental ratio 7721 pounds per QALY gained. greatest is achieved by R-CHOP followed (R-CHOP>R) this strategy had probability approximately 18,000 greater. guidance issued NICE result STA states people NHL, now option combination induce alone during remission. Rituximab monotherapy also disease all alternative options have been exhausted.